Mainz Biomed to Present at AACR 2026 Annual Meeting in San Diego.

Wednesday, Jan 14, 2026 9:31 am ET1min read
MYNZ--

Mainz Biomed will present the results of its verification study evaluating a proprietary combination of blood-derived mRNA biomarkers and AI-assisted modeling approach to differentiate pancreatic ductal adenocarcinoma (PDAC) from benign conditions at the American Association for Cancer Research (AACR) 2026 Annual Meeting. The study aimed to differentiate PDAC from benign conditions, including intraductal papillary mucinous neoplasms (IPMNs), in a 30-subject cohort.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet